tradingkey.logo

PharmaCyte Biotech Inc

PMCB
查看詳細走勢圖
0.741USD
+0.041+5.89%
收盤 02/06, 16:00美東報價延遲15分鐘
5.04M總市值
虧損本益比TTM

PharmaCyte Biotech Inc

0.741
+0.041+5.89%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.89%

5天

-9.50%

1月

-10.70%

6月

-12.80%

今年開始到現在

+2.38%

1年

-50.26%

查看詳細走勢圖

TradingKey PharmaCyte Biotech Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

PharmaCyte Biotech Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名213/392位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

PharmaCyte Biotech Inc評分

相關信息

行業排名
213 / 392
全市場排名
428 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

PharmaCyte Biotech Inc亮點

亮點風險
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值-0.66,處於3年歷史合理位
機構減倉
最新機構持股434.85K股,環比減少46.71%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉80.00K股
活躍度增加
近期活躍度增加,過去20天平均換手率4.02

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

PharmaCyte Biotech Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

PharmaCyte Biotech Inc簡介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代碼PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
網址https://pharmacyte.com/
KeyAI